Drug Hunter, Inc. Welcomes Dr. Lori Friedman to Advisory Board for Drug Discovery Push

Drug Hunter, Inc. Welcomes Dr. Lori Friedman to Advisory Board

In a significant move for the realm of drug discovery, Drug Hunter, Inc., the leading knowledge platform catering to research and development teams, proudly announces the addition of Dr. Lori Friedman, Ph.D., to its Scientific Advisory Board (SAB). This strategic appointment emphasizes Drug Hunter's commitment to expanding its reach and expertise in drug discovery disciplines.

Dr. Friedman arrives with an impressive background, joining the ranks of notable professionals such as Drs. Wendy Young, Dean Brown, Nicholas Meanwell, Daniel Erlanson, and Ken Brameld. This accomplished group works to empower scientists and R&D leaders with the vital insights they require to innovate and develop effective medicines for tomorrow. With her depth of knowledge in biology and extensive experience in drug discovery, Dr. Friedman is perfectly positioned to enhance the SAB’s capabilities.

A Visionary in Cancer Research

As the Chief Scientific Officer (CSO) at ORIC, Dr. Friedman possesses over 20 years of hands-on experience in cancer research. Her areas of expertise include cancer target discovery and validation, signal transduction, cancer genetics, pharmacology, and identifying key biomarkers. During her time as head of translational oncology at Genentech's Research and Early Development division (gRED), Dr. Friedman played an instrumental role in moving over 20 programs into clinical development, notably including inavolisib and giredestrant for breast cancer treatment.

Furthermore, her intellectual contributions can be seen through the 28 issued patents she holds and her authorship on more than 100 peer-reviewed publications. Currently, she also chairs the Chemistry in Cancer Research working group at the American Association for Cancer Research (AACR) and provides her insights as a board member for Project Scientist, a non-profit organization dedicated to inspiring girls in STEM fields, alongside her role at NextRNA Therapeutics board.

Emphasizing Growth and Collaboration

Expressing enthusiasm about her new role, Dr. Friedman stated, "I'm truly excited to join the Drug Hunter Scientific Advisory Board and contribute to a mission that resonates deeply with my own values — empowering the world's scientists to make tomorrow's medicines. It’s an honor to collaborate with such a thoughtful, talented group of industry leaders on a mission to share and amplify the insights that matter most to drug developers aiming to turn molecules into life-changing medicines."

The inclusion of Dr. Friedman on the SAB aligns with Drug Hunter’s broader goals to enhance its foundation in drug discovery biology, including a focus on biology, drug metabolism, pharmacokinetics, and overarching drug discovery strategies. Drug Hunter is already relied upon by over 200 notable organizations involved in pharmaceutical R&D, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Nimbus Therapeutics, and the National Institutes of Health (NIH).

Drug Hunter serves as an invaluable resource, providing searchable insights extracted from scientific literature, patents, and early disclosures, all meticulously distilled by a dedicated team of industry scientists. This comprehensive knowledge platform empowers researchers to navigate the complexities of drug discovery effectively.

About Drug Hunter

Founded by a team of seasoned industry scientists, Drug Hunter stands at the forefront of drug discovery. The platform operates as an essential knowledge base for R&D organizations committed to transforming molecules into medicines. By establishing connections between disparate pieces of information and synthesizing industry lessons, Drug Hunter enables scientists to make informed decisions and tackle critical challenges faced throughout the discovery process. With a steadfast dedication to advancing drug discovery, Drug Hunter continues to be a trusted partner for leading biotech and pharmaceutical R&D organizations in their quest to innovate health solutions.